Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix | BIOLOGICAL | - |
Inclusion criteria * Written informed consent will be obtained from the subject prior to entry into the study. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Seronegative for anti-HAV antibodies. * If the subject is fem...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
Hepatyrix is a combined vaccine developed by GSK plc for protection against hepatitis A and typhoid fever. It combines a Vi polysaccharide typhoid vaccine with a hepatitis A vaccine in a single formulation. It is intended for use in adults aged 18 to 50 years, particularly those at risk of both infections.
Hepatyrix is developed and manufactured by GSK plc, which trades under the ticker GSK. GSK is a global pharmaceutical company with a portfolio of vaccines and medicines.
Hepatyrix has been evaluated in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The vaccine is not described as approved in the available information, so it remains an investigational product.
Hepatyrix has been studied in a completed Phase 3 trial, NCT00197249. This trial enrolled 1,034 healthy adults aged 18 to 50 years and compared Hepatyrix with Havrix plus Typherix or Tiphim Vi, assessing reactogenicity and immunogenicity. The trial was randomized but not double-blind and used an uncontrolled design.
No, Hepatyrix is a combined vaccine that includes both hepatitis A and typhoid Vi polysaccharide components. Havrix is a separate hepatitis A vaccine, and Typherix is a separate typhoid Vi polysaccharide vaccine. Hepatyrix was compared against these separate vaccines in its clinical trial.